Propanc Health Group Corp (OTCMKTS:PPCH) a rising healthcare company concentrating on the development of proprietary treatments for cancer patients disclosed fresh new insights have appeared into the advancement and spread of carcinomas, available in the British Journal of Cancer by known researchers from the University of Glasgow. The results may have noteworthy implications for Propanc’s lead candidate, PRP, as a new measure to control cancer spread, termed as metastasis, the prime reason of patient death from cancer.
In the article, writer Professor Laura Machesky states how stringent controls on cell increase and migration needed for maintaining healthy tissues can result in problems when normal course is disrupted. The cancers resulting from these tissues, known as epithelial tissues, covering internal surfaces and organs in the human body, are termed as carcinomas. There is one feature of carcinomas linked with ‘metastatic spread’ and aggressiveness is the loss of function of epithelial integrity. It is better known as epithelial to mesenchymal transition when cancer cells turns invasive and motile, seeding new tumors. It is only beginning but she said the EMT may offer insight that becomes a noteworthy target for treating cancer.
The expert view
Dr Julian Kenyon, Propanc’s Chief Scientific Officer said that the lead product PRP uses two pancreatic proenzymes trypsinogen and chymotrypsinogen, which are enzymes in inactive status. When given to a patient, the management believes enzymes are activated at the tumor place, changing the cancer cell’s signaling lines and forcing the cell to opt for normal behavior. As a result, cancer cells die naturally.
Reversing the EMT procedure is a main feature of Propanc’s lead product PRP and is quickly translating into a reliable solution to control cancer cell migration. Propanc’s CEO James Nathanielsz said that It is motivating to see research entities from around the world concentrating their measures into better understanding of the EMT process.